SBIR/STTR Research Award

Materials for Isolation of Nucleic Acids from Whole Blood without a Lysis Step

Award identifier bcf4d73a0307a29d6eebafac6a829a6dea2717c10217de4d94a154b340d489d8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LUMIGEN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The objective of the proposed study is to develop new materials for the rapid isolation of nucleic acids from complex matrices such as whole blood. In Phase I we will prepare functionalized \microparticles for binding and releasing nucleic acids that utilize proprietary chemistry recently i developed at Lumigen. These materials find many uses but are intended particularly for the rapid ' and simplified isolation of genomic nucleic acids from unpurified or heterogeneous matrices, especially DNA in mammalian tissue or whole blood. This is made possible by a unique feature of these materials: their ability to capture DNA and/or RNA under virtually any reasonable conditions. As a result we have been able to bind DNA from whole blood without any lysis step. The prototype new materials bind nucleic acids with exceptional strength under a range of conditions and resist release under a wide variety of conditions. The unique binding properties of the new materials will be utilized to develop optimized methods for stringently washing and releasing the bound nucleic acid in a highly controllable fashion. Preliminary experiments have demonstrated that a cleavable link between the solid support and the binding moiety can be controllably severed to release nucleic acid back into solution. Nucleic acids purified with first generation materials have been found compatible with downstream applications including amplification technologies such as PCR and LMO, a ligase-based nucleic acid amplification technology invented by the PL We expect to produce one or more general use kits for isolating DNA from whole blood without any lysis step and in a quantity and quality acceptable for use in downstream amplification and diagnostic applications. For the initial phase of the project we expect to develop both non-magnetic and | magnetically responsive microparticles from different solid phase support materials. Since the j prototype new materials have shown exceptionally strong binding to nucleic acids, we plan further to begin exploring the use of the developed materials in capturing nucleic acids from low abundance viral and bacterial infectious agents from samples such as blood and other body fluids. This work serves as a prelude to the development of nucleic acid-based test methods for pathogens in human blood and food products to be undertaken in Phase II.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.